AM413

AM413 is a small molecule drug candidate developed by MAK Scientific that targets the endocannabinoid system. It is currently in the preclinical stage of development and is designed for oral administration. MAK Scientific's research focus involves modulating the endocannabinoid system through various targets, including cannabinoid receptors (CB1 and CB2) and key metabolic enzymes such as fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MGL), N-acylethanolamine-hydrolyzing amidase (NAAA), and diacylglycerol lipase (DGL). While the specific biological target for AM413 has not been publicly disclosed in detail, it belongs to a library of rationally designed cannabinergic compounds intended for the treatment of metabolic diseases, chronic liver disease, neurodegenerative disorders, and inflammatory pain.